Serial CRP (C-reactive protein) Monitoring in COVID-19 Pneumonia for the Assessment of Severity, Ventilatory Support Requirement and Predicting Early Lung Fibrosis
Keywords:COVID-19 pneumonia, CRP, Oxygen saturation, Inflammatory marker
Introduction: Robust data of CRP is available in bacterial infection, and now it can be utilized in Covid- 19 pneumonia pandemic initial assessment of severity and planning of treatment.
Materials and Methods: Multicentric, prospective, observational and interventional study conducted during July 2020 to May 2021 included 1000 Covid-19 cases confirmed with RT PCR. All cases were assessed with lung involvement documented and categorized on HRCT thorax, oxygen saturation, inflammatory marker as CRP at entry point and follow up. Age, gender, Comorbidity and use BIPAP/NIV and outcome as with or without lung fibrosis as per CT severity were key observations. Statistical analysis is done by using Chi square test.
Observations and analysis: Age (<50 and >50 years) and gender (male versus female) has significant association with CRP in predicting severity [p<0.00001] & [p<0.010] respectively. CT severity score at entry point with CRP level has significant correlation [p<0.00001] CRP level has significant association with duration of illness (Doi) [p<0.00001] Comorbidities has significant association with CRP level. [p<0.00001] CRP level has significant association with oxygen saturation [p<0.00001] BIPAP/NIV requirement during hospitalization has significant association with CRP level. [p<0.00001] Timing of BIPAP/NIV requirement has significant association with CRP level. [p<0.00001] Follow-up CRP titer during hospitalization as compared to entry point normal and abnormal CRP has significant association in post-covid lung fibrosis [p<0.00001]
Conclusion: CRP is easily available and universally acceptable inflammatory marker in Covid-19 pandemic and ‘serial titer’ documented very crucial role in predicting severity of illness, need of ventilatory support and help in predicting post-covid lung fibrosis.
J MEDICINE 2022; 23: 112-120
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).